Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Alimera Sciences Inc. | YUTIQ (fluocinolone acetonide intravitreal implant) - (CALM) | Non-infectious uveitis | Phase 3 | Enrollment Conclusion | Intravitreal | Opthalmic |
| Alkermes plc | Nemvaleukin (ALKS 4230) - (ARTISTRY-7) | Ovarian cancer | Phase 3 | Trial Discontinued | Intravenous | Oncology |
| Alkermes plc | Nemvaleukin (ALKS 4230) - (ARTISTRY-6) | Melanoma | Phase 2 | Trial Discontinued | Intravenous | Oncology |
| Alkermes plc | Diroximel fumarate (BIIB098) - (Head-to-head trial versus Tecfidera) | Relapsing Remitting Multiple Sclerosis (RRMS) | Phase 3 | Trial Completed | Oral | Neurology |
| Alkermes plc | Alixorexton (ALKS 2680) - (Vibrance-2) | Narcolepsy and excessive daytime sleepiness | Phase 3 | Trial Planned | Oral | Neurology |
| Alkermes plc | Nemvaleukin + KEYTRUDA (pembrolizumab) - (ION-01) | Recurrent or metastatic head and neck squamous cell carcinoma | Phase 2 | Data Released | Intravenous | Oncology |
| Alkermes plc | Nemvaleukin + KEYTRUDA (pembrolizumab) - (ION-01) | Recurrent or metastatic head and neck squamous cell carcinoma | Phase 2 | Data Released | Intravenous | Oncology |
| Alkermes plc | ALKS 2680 - (Vibrance-3) | Idiopathic Hypersomnia | Phase 2 | Enrollment Initiation | Oral | Neurology |
